AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39272232 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA risk genotypes
Number of subjects: 2832
Study 39272766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Number of subjects: 0
Study 39273147 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating neoplastic-immune hybrid cells (CHCs) identified by co-expression of pan-cytokeratin (CK) and CD45, levels correlated to clinical disease course.
Number of subjects: 5
Study 39273147 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-resistant CHCs
Number of subjects: 5
Study 39273147 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trial surveillance
Number of subjects: 5
Study 39273147 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning analysis of CHCs
Number of subjects: 5
Study 39273470 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 38
Study 39274199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia definitions
Number of subjects: 0
Study 39274199 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle power reduction
Number of subjects: 0
Study 39274238 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Specific Perceived Harmfulness
Number of subjects: 0
Study 39274500 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Step Early Intervention Program
Number of subjects: 0
Study 39275135 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio Diet
Number of subjects: 0
Study 39275135 — intervention group
Group type: COMPARATOR
Intervention: Control Diet
Number of subjects: 0
Study 39275279 — intervention group
Group type: EXPERIMENTAL
Intervention: Si.Pi.Mi (silymarin, pyrroloquinoline quinone sodium salt, and myricetin)
Number of subjects: 20
Study 39275314 — intervention group
Group type: EXPERIMENTAL
Intervention: FX supplementation
Number of subjects: 43
Study 39276176 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353 plus pembrolizumab (arm A; MK-8353 50-350 mg twice daily)
Number of subjects: 110
Study 39276176 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353 plus pembrolizumab (arm B; MK-8353 50-600 mg once daily)
Number of subjects: 110
Study 39276176 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353 plus pembrolizumab (arm C; MK-8353 50-300 mg once daily every other week)
Number of subjects: 110
Study 39276185 — intervention group
Group type: EXPERIMENTAL
Intervention: Iparomlimab (3 mg/kg, intravenous, once every 3 weeks)
Number of subjects: 71
Study 39276275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS)
Number of subjects: 16
Study 39276443 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education program based on Individual and Family Self-Management Theory
Number of subjects: 72
Study 39276443 — intervention group
Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 72
Study 39276619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF/RSV preF protein vaccine (different doses of Ad26.RSV.preF with fixed dose of RSV preF protein 150 μg)
Number of subjects: 454
Study 39276619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 39276782 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time estimation of antibody kinetics against SARS-CoV-2 variants (delta, BA.2, XBB 1.5)
Number of subjects: 968
Study 39276782 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time dataset of neutralising-antibody titres
Number of subjects: 968
Study 39276782 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective dataset of neutralising-antibody titres
Number of subjects: 968
Study 39276785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks until disease progression
Number of subjects: 41
Study 39276867 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling (n=8)
Number of subjects: 13
Study 39276867 — intervention group
Group type: COMPARATOR
Intervention: No ILM peeling (n=5)
Number of subjects: 13
Study 39276867 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 13
Study 39277028 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146
Study 39277028 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 146
Study 39277029 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of heart failure patients at high risk for hyperkalemia
Number of subjects: 2558
Study 39277116 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP2 concentration in human milk
Number of subjects: 52
Study 39277116 — intervention group
Group type: COMPARATOR
Intervention: Maternal weight status (normal weight vs overweight/obesity)
Number of subjects: 52
Study 39277116 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant plasma LEAP2 concentration
Number of subjects: 52
Study 39277170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouge Grossesse application (coaching program and a pedometer; n=125)
Number of subjects: 250
Study 39277170 — intervention group
Group type: COMPARATOR
Intervention: Placebo application (pedometer only; n=125)
Number of subjects: 250
Study 39277170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouge Grossesse application
Number of subjects: 250
Study 39277170 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 250
Study 39277203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention involving Orthodox priests and Health Development Army members conducting community health outreach.
Number of subjects: 300
Study 39277203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 300
Study 39277672 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab-deruxtecan plus durvalumab (block A)
Number of subjects: 106
Study 39277672 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab-deruxtecan plus durvalumab (after blocks A + B)
Number of subjects: 106
Study 39277672 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 106
Study 39277671 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab-deruxtecan (Dato-DXd)
Number of subjects: 103
Study 39277671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential multiple assignment randomization trial design including three blocks: block A (experimental agent), block B (taxane-based regimen), block C (doxorubicin-cyclophosphamide)
Number of subjects: 103
Study 39277739 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (15 µg/subtype/0.5 ml/dose)
Number of subjects: 1399
Study 39277837 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stabilization with thoracic belt
Number of subjects: 36
Study 39277837 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no thoracic belt)
Number of subjects: 36
Study 39278126 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-focused multicomponent exercise program (twice-weekly for 6 months)
Number of subjects: 148
Study 39278284 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep endotracheal intubation (DET)
Number of subjects: 59
Study 39278284 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal intubation (CET)
Number of subjects: 59
Study 39278393 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature control practices; 75% survey response rate, 80% sites have protocols, 62.5% have ED-specific protocols.
Number of subjects: 51
Study 39278393 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of neuromuscular blockade (NMB) during temperature control induction; 61.7% of sites induced paralysis less than 20% of the time.
Number of subjects: 51
Study 39278393 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of temperature control; 83.3% of protocols emphasized early initiation, but 62.5% reported clinical nihilism as a barrier.
Number of subjects: 51
Study 39278393 — intervention group
Group type: EXPERIMENTAL
Intervention: NMB usage; 1 in 2 patients treated with NMB, but variability in use and timing of temperature control device initiation.
Number of subjects: 51
Study 39278411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-3 supplementation (3000 IU daily)
Number of subjects: 720
Study 39278411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 39278792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary syndromes (ACS)
Number of subjects: 419
Study 39278792 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic coronary syndrome (CCS)
Number of subjects: 419
Study 39278792 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater plaque burden
Number of subjects: 419
Study 39278920 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional strategies used by healthcare professionals (suppressing and modifying emotions, distancing from residents)
Number of subjects: 93
Study 39278920 — intervention group
Group type: EXPERIMENTAL
Intervention: Acknowledging emotional labour
Number of subjects: 93
Study 39278920 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational culture that supports emotional expression
Number of subjects: 93
Study 39278928 — intervention group
Group type: EXPERIMENTAL
Intervention: VRVT plus single-vision spectacle (SVS)
Number of subjects: 65
Study 39278928 — intervention group
Group type: COMPARATOR
Intervention: Only SVS without receiving VRVT (Control)
Number of subjects: 65
Study 39278994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg) plus Relatlimab (480 mg) for two 4-weekly cycles
Number of subjects: 59
Study 39279257 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg dose of melatonin 1 hour before bedtime for 6 weeks
Number of subjects: 80
Study 39279257 — intervention group
Group type: COMPARATOR
Intervention: Standard sleep hygiene (≥6 hours per night, avoiding caffeine and naps in the evening)
Number of subjects: 80
Study 39279266 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Aspirate Concentrate (BMAC) injection during APM
Number of subjects: 95
Study 39279266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMAC)
Number of subjects: 95
Study 39279266 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAC group
Number of subjects: 95
Study 39279371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=162) received two 2-h interventions combining Sharing, Mind and Enjoyment (SME), Zero-time Exercises (ZTEx), positive psychology, and simple family games.
Number of subjects: 314
Study 39279371 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=152) received interventions unrelated to SME.
Number of subjects: 314
Study 39279371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=162)
Number of subjects: 314
Study 39279371 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=152)
Number of subjects: 314
Study 39279436 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic RTEL1 variants
Number of subjects: 44
Study 39279580 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily plus androgen-deprivation therapy (ADT)
Number of subjects: 669
Study 39279580 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus androgen-deprivation therapy (ADT)
Number of subjects: 669
Study 39279639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cagrilintide (4.5 mg, once-weekly subcutaneous injection)
Number of subjects: 105
Study 39279639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 39279639 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, oral)
Number of subjects: 105
Study 39279639 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin placebo
Number of subjects: 105
Study 39279719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (L) and zeaxanthin (Z) concentrations measured by HPLC
Number of subjects: 42
Study 39279766 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic radiosurgery (SRS)
Number of subjects: 48
Study 39279766 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 48
Study 39279973 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + Anlotinib
Number of subjects: 38
Study 39279973 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 38
Study 39280033 — intervention group
Group type: COMPARATOR
Intervention: No RVD
Number of subjects: 648
Study 39280033 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset RVD
Number of subjects: 648
Study 39280033 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized RVD
Number of subjects: 648
Study 39280033 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual RVD
Number of subjects: 648
Study 39280041 — intervention group
Group type: EXPERIMENTAL
Intervention: DanceMove (step-based activity)
Number of subjects: 70
Study 39280041 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control)
Number of subjects: 70
Study 39280784 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-Well online modules
Number of subjects: 100
Study 39280784 — intervention group
Group type: COMPARATOR
Intervention: ISR e-bulletins
Number of subjects: 100
Study 39280785 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple electroacupuncture weekly treatment group (group M) - 12 sessions (3 sessions per week)
Number of subjects: 80
Study 39280785 — intervention group
Group type: COMPARATOR
Intervention: Single electroacupuncture weekly treatment group (group S) - 4 sessions (1 session per week)
Number of subjects: 80
Study 39280787 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously
Number of subjects: 0
Study 39280787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39280895 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Monitoring Strategy
Number of subjects: 0
Study 39280922 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation mt-sDNA test
Number of subjects: 7022
Study 39281099 — intervention group
Group type: EXPERIMENTAL
Intervention: toripalimab plus definitive chemoradiotherapy (CRT)
Number of subjects: 42
Study 39281103 — intervention group
Group type: EXPERIMENTAL
Intervention: IQCS (Intelligent Quality-Control System)
Number of subjects: 1840
Study 39281103 — intervention group
Group type: COMPARATOR
Intervention: Routine OGD
Number of subjects: 1840
Study 39281698 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA exon editing
Number of subjects: 0
Study 39281732 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified WHO Labour Care Guide (LCG)
Number of subjects: 2011
Study 39281732 — intervention group
Group type: COMPARATOR
Intervention: Partograph
Number of subjects: 2011
Study 39281757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle factors (diet, sleep, and physical activity) monitored using wearables and continuous glucose monitoring
Number of subjects: 36
Study 39281757 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated ML models using lifestyle factors
Number of subjects: 36
Study 39281809 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index
Number of subjects: 362
Study 39281809 — intervention group
Group type: EXPERIMENTAL
Intervention: International Index of Erectile Function
Number of subjects: 362
Study 39281809 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Sexual Distress Scale-Revised
Number of subjects: 362
Study 39281809 — intervention group
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Sexual Health
Number of subjects: 362
Study 39281809 — intervention group
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
Number of subjects: 362
Study 39281971 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sasanlimab 300 mg once every 4 weeks (300 mg-Q4W)
Number of subjects: 155
Study 39281971 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sasanlimab 600 mg once every 6 weeks (600 mg-Q6W)
Number of subjects: 155
Study 39281978 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 0
Study 39282041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of calcium gluconate
Number of subjects: 34
Study 39282041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 39282367 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR8 agonism and anti-PD-1 blockade
Number of subjects: 0
Study 39282508 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided volume of tissue activated (IG-VTA) programming
Number of subjects: 26
Study 39282508 — intervention group
Group type: COMPARATOR
Intervention: Conventional ring-mode programming (CP-RM)
Number of subjects: 26
Study 39282663 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 39282663 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 39282750 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE)
Number of subjects: 65
Study 39282762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance (FB) adjusted serum creatinine (SCr) values
Number of subjects: 131
Study 39282762 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AKI
Number of subjects: 131
Study 39282854 — intervention group
Group type: EXPERIMENTAL
Intervention: iltamiocel
Number of subjects: 311
Study 39282854 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 311
Study 39282896 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 866
Study 39282896 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (physician's choice)
Number of subjects: 866
Study 39282897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Number of subjects: 0
Study 39282897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks plus placebo)
Number of subjects: 0
Study 39282897 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg every 3 weeks for four doses plus placebo)
Number of subjects: 0
Study 39282902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for 1 year)
Number of subjects: 702
Study 39282902 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 702
Study 39282907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsegromab 100 mg
Number of subjects: 187
Study 39282907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsegromab 200 mg
Number of subjects: 187
Study 39282907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsegromab 400 mg
Number of subjects: 187
Study 39282907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 39282905 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy plus perioperative chemotherapy
Number of subjects: 574
Study 39282905 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy alone (control)
Number of subjects: 574
Study 39282905 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 574
Study 39282905 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (control)
Number of subjects: 574
Study 39282913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 298
Study 39282906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy group
Number of subjects: 1174
Study 39282906 — intervention group
Group type: COMPARATOR
Intervention: Placebo-chemotherapy group
Number of subjects: 1174
Study 39282910 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine-cisplatin every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks for eight cycles.
Number of subjects: 1063
Study 39282910 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone.
Number of subjects: 1063
Study 39282910 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine-cisplatin.
Number of subjects: 1063
Study 39283020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of coherence scale
Number of subjects: 136
Study 39283020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercultural sensitivity scale
Number of subjects: 136
Study 39283020 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related strain inventory
Number of subjects: 136
Study 39283176 — intervention group
Group type: EXPERIMENTAL
Intervention: Take a STAND for Health (TS4H)
Number of subjects: 103
Study 39283176 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 103
Study 39283178 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visitation
Number of subjects: 38
Study 39283227 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 60
Study 39283227 — intervention group
Group type: EXPERIMENTAL
Intervention: EX
Number of subjects: 60
Study 39283231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted exercise training (exercise after an overnight fast)
Number of subjects: 20
Study 39283231 — intervention group
Group type: COMPARATOR
Intervention: Postprandial exercise training (exercise after morning meal)
Number of subjects: 20
Study 39283231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted exercise training
Number of subjects: 20
Study 39283231 — intervention group
Group type: COMPARATOR
Intervention: Postprandial exercise training
Number of subjects: 20
Study 39283234 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, goal-oriented intervention; details on dosage and duration not specified.
Number of subjects: 0
Study 39283234 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 39283252 — intervention group
Group type: EXPERIMENTAL
Intervention: Family functioning (support and bonding)
Number of subjects: 0
Study 39283252 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss program (WW)
Number of subjects: 0
Study 39283252 — intervention group
Group type: COMPARATOR
Intervention: Self-guided group
Number of subjects: 0
Study 39283290 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib 400 mg orally daily, 28-day cycle
Number of subjects: 25